Prenetics Global (NASDAQ:PRE) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Prenetics Global (NASDAQ:PRE) announced its quarterly earnings data on Monday. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.14, Zacks reports. Prenetics Global had a negative net margin of 87.92% and a negative return on equity of 31.05%. The business had revenue of $23.56 million during the quarter, compared to analyst estimates of $26.00 million. Prenetics Global updated its FY 2025 guidance to EPS.

Prenetics Global Trading Down 3.6%

PRE stock opened at $11.89 on Tuesday. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $17.99. The business’s 50 day moving average is $12.80 and its 200-day moving average is $9.48. The firm has a market cap of $200.08 million, a P/E ratio of -4.83 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PRE shares. Cantor Fitzgerald boosted their price target on Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Prenetics Global has an average rating of “Hold” and an average target price of $32.00.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. JPMorgan Chase & Co. acquired a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,900 shares of the company’s stock, valued at approximately $65,000. 25.01% of the stock is owned by hedge funds and other institutional investors.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.